UPMC Enterprises Leads Investment Round in Carta Healthcare to Advance AI-Powered Clinical Data Management

UPMC Enterprises is thrilled to announce our investment in Carta Healthcare, a leading provider of AI-powered clinical data management. UPMC Enterprises led Carta’s latest round of funding, an $18.25 Million Series B1 round that included a broad array of strategic investors.

Leveraging the Series B1 funding, along with technology acquired in the purchase of Realyze Intelligence from UPMC Enterprises late in 2024, Carta Healthcare will continue to expand its customer footprint, particularly in the life sciences market.

Carta Healthcare recognizes the importance of clinical data management to improving access to care, enhancing patient outcomes, and advancing cutting-edge treatments through clinical trials. UPMC Enterprises, the innovation, commercialization, and venture capital arm of UPMC, is proud to be an investor in a company that is aligned with our system’s goal of delivering life-changing medicine to patients.

“UPMC Enterprises invests in companies that are solving real problems in health care delivery,” said Brent Burns, executive vice president at UPMC Enterprises. “Health systems face significant challenges associated with clinical data management and patient trial matching, which are time-consuming, labor-intensive processes. Carta Healthcare leverages AI to streamline data abstraction and provide analytics that clinicians can use to improve patient care. We look forward to partnering with Carta Healthcare to advance their mission and explore opportunities to implement their solutions across our health system.”

Carta Healthcare: The Future of Clinical Data Management Powered by AI

Carta Healthcare supports providers and patients by harnessing the power of clinical data by ensuring that accurate, reliable, and consistent data can be used to make informed decisions about treatment. Carta Healthcare is innovating to deliver better patient outcomes through its personalized treatment plans, enrollment of patients into clinical trials, and development of new treatments and therapies.

Carta Healthcare’s technology transforms clinical data abstraction through the use of AI and expert abstractors. The process converts both structured and unstructured health care data into high-quality, standardized datasets, which allows providers to improve patient outcomes and operational efficiency by leveraging accurate and reliable data.

Carta’s unique solutions are designed to be faster, more cost-effective, and higher quality compared with traditional methods of data abstraction which are often more labor-intensive, time-consuming, and costly. Applying innovative techniques, expertise, and technologies are essential to changing the paradigm around data abstraction, improving patient experiences, and advancing medicine.

UPMC Enterprises’ investment, with participation from new strategic investors MemorialCare Innovation Fund, Rex Health Ventures, Tampa General Hospital Ventures and support from existing investors Memorial Hermann Health System, Frist Cressey Ventures, Storm Ventures, Paramark Ventures, CU Healthcare Innovation Fund, and Mass General Brigham Ventures, demonstrates the UPMC commitment to outstanding patient care and access.

“This significant investment from leading health systems further validates and empowers our mission to harness the power of data, ensuring that care teams and researchers have the information they need, when they need it,” Carta Healthcare CEO Brent Dover said. “With their support and adoption of our solutions, we can continue to expand on our deep clinical domain expertise, scale our operations and product deployment, and activate their unstructured data as close to real time as possible to support process improvement and quality initiatives.”

Empowering Clinicians and Improving Patient Outcomes with Data

With this round of funding from UPMC Enterprises and other investors, along with the recent acquisition of Realyze Intelligence, Carta Healthcare is positioned for success. Realyze, which was spun out of UPMC Enterprises, has strategic capabilities in oncology, automating the abstraction of data, and workflow for clinical trial matching. The Realyze solution leverages AI to match patients to clinical trials which accelerates research and reduces costs while providing patients with the latest advances in care.

Atlas, Carta’s AI-driven platform, automates the extraction and standardization of clinical data for registry submissions, improving accuracy and efficiency, and supporting Carta’s advancement in clinical data abstraction.

Additionally, the company can further improve operational analytics for health care providers through Navigator, a tool that uses health care data to address operational challenges such as anesthesia coverage and operating room scheduling.

Perhaps most aligned to our mission, Carta Healthcare improves patient care by providing near-real-time access to standardized data, empowering health care providers to make the most informed decisions possible. These innovative solutions support health care organizations in streamlining processes and improving overall care quality.

Next Steps

• Learn more about Carta Healthcare and its technology at Carta.Healthcare.
• Find out more about Carta Healthcare’s recent acquisition of Realyze Intelligence.
• Download the research report, “Opportunity for Improvement: Performance of Clinical Trials Programs at Academic Medical Centers.”